Stock listing
Frankfurt:XE7C Cardiff Oncology, Inc. Aktie
German listing (Frankfurt) of Cardiff Oncology, Inc. · home listing NASDAQ:CRDF
Follow Cardiff Oncology, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CRDF
$0.853 USD +0.014 (+1.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRDF
- Day range
- $0.832 – $0.904 USDNov 20, 2026
- Volume
- 520,597 sharesNov 20, 2026
- Market cap
- $66.34M USDAt the close on Nov 20, 2026 · price × 77.80M shares outstanding
- 52-week range
- $0.711 – $3.310 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $977,633 USDMedian day 504,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRDF · Home | $0.853 USD | +0.014 (+1.6%) | 520,597 | $0.884 | $0.904 | $0.832 | $0.839 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRDF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.853 | +0.014 | +1.6% | $0.884 | $0.904 | $0.832 | 520,597 | |
| $0.839 | -0.007 | -0.9% | $0.840 | $0.876 | $0.813 | 857,601 | |
| $0.846 | -0.001 | -0.2% | $0.870 | $0.909 | $0.790 | 1,974,553 | |
| $0.848 | +0.122 | +16.7% | $0.795 | $0.937 | $0.795 | 24,873,651 | |
| $0.726 | -0.002 | -0.2% | $0.728 | $0.735 | $0.711 | 204,773 | |
| $0.728 | -0.038 | -4.9% | $0.750 | $0.762 | $0.720 | 313,779 | |
| $0.765 | -0.029 | -3.7% | $0.780 | $0.810 | $0.755 | 333,991 | |
| $0.795 | -0.006 | -0.7% | $0.780 | $0.810 | $0.760 | 158,725 | |
| $0.801 | +0.005 | +0.7% | $0.800 | $0.836 | $0.780 | 397,137 | |
| $0.795 | +0.040 | +5.3% | $0.798 | $0.798 | $0.760 | 345,290 | |
| $0.755 | -0.114 | -13.1% | $0.852 | $0.852 | $0.750 | 708,031 | |
| $0.869 | +0.006 | +0.7% | $0.867 | $0.900 | $0.844 | 289,019 | |
| $0.863 | +0.019 | +2.2% | $0.850 | $0.884 | $0.841 | 224,953 | |
| $0.844 | -0.045 | -5.1% | $0.898 | $0.910 | $0.833 | 467,348 | |
| $0.890 | -0.022 | -2.5% | $0.900 | $0.921 | $0.858 | 126,854 | |
| $0.912 | +0.014 | +1.6% | $0.902 | $0.950 | $0.900 | 123,203 | |
| $0.898 | +0.022 | +2.6% | $0.870 | $0.950 | $0.850 | 280,536 | |
| $0.875 | +0.071 | +8.8% | $0.820 | $0.890 | $0.781 | 637,049 | |
| $0.804 | -0.103 | -11.4% | $0.890 | $0.950 | $0.790 | 866,649 | |
| $0.907 | -0.023 | -2.4% | $0.920 | $0.940 | $0.885 | 174,285 | |
| $0.930 | -0.010 | -1.1% | $0.930 | $0.970 | $0.910 | 228,700 | |
| $0.940 | +0.010 | +1.1% | $0.950 | $0.970 | $0.920 | 436,800 | |
| $0.930 | +0.040 | +4.5% | $0.910 | $0.980 | $0.880 | 595,200 | |
| $0.890 | -0.010 | -1.1% | $0.920 | $0.930 | $0.880 | 425,700 | |
| $0.900 | -0.070 | -7.2% | $0.980 | $0.990 | $0.890 | 515,500 | |
| $0.970 | 0.000 | 0.0% | $0.950 | $1.000 | $0.950 | 453,800 | |
| $0.970 | -0.040 | -4.0% | $1.060 | $1.060 | $0.960 | 412,900 | |
| $1.010 | -0.030 | -2.9% | $1.040 | $1.050 | $1.000 | 504,800 | |
| $1.040 | -0.040 | -3.7% | $1.080 | $1.080 | $1.040 | 377,200 | |
| $1.080 | +0.020 | +1.9% | $1.060 | $1.110 | $1.060 | 297,400 | |
| $1.060 | -0.030 | -2.8% | $1.070 | $1.080 | $1.050 | 541,000 | |
| $1.090 | +0.020 | +1.9% | $1.070 | $1.130 | $1.070 | 457,500 | |
| $1.070 | -0.070 | -6.1% | $1.150 | $1.160 | $1.060 | 384,200 | |
| $1.140 | +0.020 | +1.8% | $1.100 | $1.150 | $1.090 | 451,900 | |
| $1.120 | -0.060 | -5.1% | $1.210 | $1.210 | $1.110 | 628,300 | |
| $1.180 | -0.030 | -2.5% | $1.220 | $1.220 | $1.160 | 298,400 | |
| $1.210 | +0.040 | +3.4% | $1.170 | $1.250 | $1.170 | 564,600 | |
| $1.170 | -0.030 | -2.5% | $1.190 | $1.240 | $1.160 | 353,000 | |
| $1.200 | -0.040 | -3.2% | $1.230 | $1.230 | $1.190 | 377,400 | |
| $1.240 | -0.040 | -3.1% | $1.300 | $1.300 | $1.230 | 563,400 | |
| $1.280 | -0.030 | -2.3% | $1.300 | $1.320 | $1.250 | 596,300 | |
| $1.310 | -0.020 | -1.5% | $1.320 | $1.340 | $1.280 | 590,100 | |
| $1.330 | -0.040 | -2.9% | $1.370 | $1.390 | $1.330 | 518,500 | |
| $1.370 | 0.000 | 0.0% | $1.390 | $1.410 | $1.360 | 476,000 | |
| $1.370 | +0.070 | +5.4% | $1.290 | $1.390 | $1.290 | 737,800 | |
| $1.300 | -0.050 | -3.7% | $1.360 | $1.380 | $1.260 | 1,131,900 | |
| $1.350 | +0.010 | +0.7% | $1.350 | $1.380 | $1.310 | 1,852,300 | |
| $1.340 | +0.030 | +2.3% | $1.420 | $1.510 | $1.310 | 3,168,500 | |
| $1.310 | +0.100 | +8.3% | $1.230 | $1.340 | $1.220 | 2,100,100 | |
| $1.210 | 0.000 | 0.0% | $1.210 | $1.220 | $1.170 | 493,300 | |
| $1.210 | +0.160 | +15.2% | $1.050 | $1.220 | $1.030 | 744,600 | |
| $1.050 | -0.050 | -4.5% | $1.080 | $1.080 | $1.020 | 716,000 | |
| $1.100 | +0.010 | +0.9% | $1.050 | $1.130 | $1.050 | 708,200 | |
| $1.090 | +0.010 | +0.9% | $1.080 | $1.100 | $1.070 | 437,300 | |
| $1.080 | +0.020 | +1.9% | $1.070 | $1.090 | $1.040 | 375,500 | |
| $1.060 | +0.030 | +2.9% | $1.040 | $1.090 | $1.010 | 700,800 | |
| $1.030 | +0.040 | +4.0% | $1.010 | $1.070 | $1.000 | 838,800 | |
| $0.990 | +0.050 | +5.3% | $0.940 | $1.010 | $0.900 | 590,400 | |
| $0.940 | -0.050 | -5.1% | $0.990 | $0.990 | $0.930 | 527,300 | |
| $0.990 | +0.010 | +1.0% | $0.980 | $1.000 | $0.980 | 202,200 | |
| $0.980 | -0.040 | -3.9% | $1.020 | $1.030 | $0.980 | 274,300 | |
| $1.020 | +0.020 | +2.0% | $1.000 | $1.070 | $0.980 | 918,500 | |
| $1.000 | +0.120 | +13.6% | $0.940 | $1.050 | $0.930 | 1,685,300 | |
| $0.880 | -0.030 | -3.3% | $0.930 | $0.930 | $0.880 | 651,900 | |
| $0.910 | +0.010 | +1.1% | $0.910 | $0.920 | $0.870 | 554,200 |
Splits
4 splits since 2004 · NASDAQ:CRDF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-6 | Consolidation | |
| 111-for-1 | Split |
- Ticker
- Frankfurt:XE7C
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 34 slides
Latest news
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Nov 16, 2026
Closed $0.848 (+16.7%) on Nov 16, 2026
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
Nov 12, 2026
Closed $0.728 (-4.9%) on Nov 12, 2026
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
Nov 3, 2026
Closed $0.863 (+2.2%) on Nov 3, 2026
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Oct 27, 2026
Closed $0.898 (+2.6%) on Oct 28, 2026
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Oct 21, 2026
Closed $0.93 (-1.1%) on Oct 22, 2026
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Sep 14, 2026
Closed $1.31 (+8.3%) on Sep 14, 2026
Cardiff Oncology to Participate in September 2026 Conferences
Sep 2, 2026
Closed $1.06 (+2.9%) on Sep 2, 2026
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Aug 11, 2026
Closed $0.99 (-5.7%) on Aug 12, 2026
Cardiff Oncology Announces $10 Million Registered Direct Offering
Jul 15, 2026
Closed $0.89 (-32.1%) on Jul 15, 2026
Cardiff Oncology, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 124 in all · newest Nov 16, 2026 · oldest 2020
- Calls
- 5 calls with a replay · 5 with a transcript · latest Feb 28, 2025
- Decks
- 93 decks · latest October 2026
Where Cardiff Oncology, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRDF · Home listing | NASDAQ | United States | USD |
| gettex:XE7C | gettex | Germany | EUR |
| LS Exchange:A2P4GU | LS Exchange | Germany | EUR |
| BOATS:CRDF | BOATS | United States | USD |
| Lang & Schwarz:A2P4GU | Lang & Schwarz | Germany | EUR |
| Frankfurt:XE7C · This page | Frankfurt | Germany | EUR |
| Dusseldorf:XE7C | Dusseldorf | Germany | EUR |
| Munich:XE7C | Munich | Germany | EUR |
| Stuttgart:XE7C | Stuttgart | Germany | EUR |
| Tradegate:XE7C | Tradegate | Germany | EUR |
Valuation
EV/sales 58.7× against a median of 14.3×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $32.82M USD
- P/E
- Loss
- EV/sales
- 58.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.4×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.32
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| ABIONYX Pharma SA · EURONEXT:ABNX | US$68.39M | US$55.55M | n/a | 12.4× | n/a | 4.0× | −136.6% | 1.0× | n/a |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.22M | US$47.02M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.61M | US$44.54M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Atara Biotherapeutics, Inc. · NASDAQ:ATRA | US$64.49M | US$64.14M | n/a | 16.2× | n/a | n/a | −368.6% | n/a | 1.43 |
| Median of the others | US$66.45M | US$51.13M | 14.3× | 3.0× | −159.5% | 0.0× | 1.43 |
Forecasts
2 strong buy · 1 buy · 3 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.28 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.56 · 3 analysts
- Revenue, year to Dec 2026
- 364.5K · 6 analysts
Team and board
| Officer | Role |
|---|---|
| Mani Mohindru | President & Chief Executive Officer |
| Joshua Muntner | Chief Financial Officer |
| Ajay Aggarwal | Chief Operating Officer |
| Brigitte Lindsay | Chief Accounting Officer |
| Leila Alland | Interim Chief Medical Officer |
| Tod Smeal | Chief Scientific Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Cardiff Oncology (NASDAQ:CRDF) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:30 PM ET | Replay |
| Cardiff Oncology (NASDAQ:CRDF) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
| Cardiff Oncology (NASDAQ:CRDF) Q1 2024 Earnings Call | Thu, May 02, 2024 · 4:30 PM ET | Replay |
| Cardiff Oncology (NASDAQ:CRDF) Q4 2023 Earnings Call | Thu, Feb 29, 2024 · 4:30 PM ET | Replay |
| Cardiff Oncology (NASDAQ:CRDF) Q3 2023 Earnings Call | Thu, Nov 02, 2023 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −4.9% |
| Q2 2026 | Aug 11, 2026 · After close | −5.7% |
| Q1 2026 | May 14, 2026 · After close | −3.5% |
| Q4 2025 | Feb 24, 2026 · After close | +12.3% |
| Q3 2025 | Nov 6, 2025 · After close | −2.7% |
| Q2 2025 | Jul 29, 2025 · After close | −24.8% |
| Q1 2025 | May 8, 2025 · After close | +1.1% |
| Q4 2024 | Feb 26, 2025 · After close | −9.0% |
| Q3 2024 | Nov 7, 2024 · After close | −24.7% |
| Q2 2024 | Aug 8, 2024 · After close | +11.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | −21.4% |
| Q4 2023 | Feb 29, 2024 · After close | +64.4% |
| Q3 2023 | Nov 2, 2023 · After close | −2.6% |
| Q2 2023 | Aug 9, 2023 · After close | +8.4% |
| Q1 2023 | May 4, 2023 · After close | −3.6% |
| Q4 2022 | Mar 2, 2023 · After close | +1.7% |
| Q3 2022 | Nov 3, 2022 · After close | 0.0% |
| Q2 2022 | Aug 4, 2022 · After close | +4.5% |
| Q1 2022 | May 5, 2022 · After close | −1.5% |
| Q4 2021 | Feb 24, 2022 · After close | +7.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 34 slides | October 2026 |
| Technical Presentation (June 2026) | Technical | 27 slides | Jun 3, 2026 |
| Investor Presentation (February 2026) | Investor deck | 39 slides | Feb 25, 2026 |
| Investor Presentation (January 2026) | Investor deck | 68 slides | January 2026 |
| Investor Presentation (October 2025) | Investor deck | 70 slides | October 2025 |
| Investor Presentation (August 2025) | Investor deck | 74 slides | August 2025 |
| Technical Presentation (July 2025) | Technical | 41 slides | Jul 29, 2025 |
| Corporate Update (July 2025) | Corporate update | 41 slides | Jul 29, 2025 |
| Investor Presentation (June 2025) | Investor deck | 92 slides | June 2025 |
| Investor Presentation (January 2025) | Investor deck | 92 slides | January 2025 |
Show 50 decks
This page holds 50 of 93 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and warrants Closed: US$10M raised · US$1.05 a share · ½ warrant at US$1.31 for 66 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Certain officers and directors (731,707 shares and accompanying warrants at $1.435 per share and accompanying warrant) Insiders: Certain officers and directors are buying 731,707 shares and accompanying warrants at $1.435 per share and accompanying warrant Use of proceeds: Working capital and general corporate purposes | Aug 11, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 593.0K | 683.0K | 488.0K | 386.0K | 359.0K | 366.0K | 244.6K | 378.3K | 505.4K | 381.1K |
| Cost of revenue | 904.0K | 404.0K | 398.0K | 200.0K | 500.0K | 11.2M | 0 | 597.5K | 1.81M | 1.73M |
| Gross profit | 593.0K | 683.0K | 488.0K | 386.0K | 359.0K | 366.0K | 244.6K | -219.0K | -1.31M | -1.35M |
| Research and development | 35.3M | 36.9M | 32.9M | 27.1M | 17.4M | 11.2M | 11.2M | 8.16M | 7.88M | 15.0M |
| Selling, general and administrative | 14.2M | 12.5M | 13.0M | 13.2M | 11.8M | 8.22M | 5.76M | 8.01M | 14.2M | 11.5M |
| Operating income | -49.0M | -48.7M | -45.4M | -39.9M | -28.9M | -19.1M | -16.7M | -17.1M | -25.6M | -40.1M |
| Depreciation and amortization | 364.0K | 404.0K | 398.0K | 236.0K | 451.0K | 466.0K | 494.2K | 859.5K | 1.25M | 1.07M |
| EBITDA | -48.6M | -48.2M | -45.0M | -39.7M | -28.4M | -18.6M | -16.2M | -16.2M | -24.3M | -39.1M |
| Interest expense | 1.58M | 0 | 2.00K | 0 | 25.4K | 1.03M | 1.67M | |||
| Income before tax | -45.9M | -45.4M | -41.4M | -38.7M | -28.3M | -19.3M | -16.4M | -16.5M | -24.9M | -39.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -45.9M | -45.4M | -41.4M | -38.7M | -28.3M | -19.3M | -16.4M | -16.5M | -24.9M | -39.2M |
| Earnings per share, basic | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 | -8.26 | -51.76 | -1.30 |
| Earnings per share, diluted | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 | -8.26 | -51.76 | -1.37 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.5M | 51.5M | 21.7M | 16.3M | 11.9M | 131.0M | 10.2M | 11.5M | 8.23M | 13.9M |
| Short-term investments | 40.8M | 40.3M | 53.2M | 88.9M | 128.9M | 0 | 0 | 24.0M | ||
| Receivables | 182.0K | 773.0K | 288.0K | 771.0K | 535.0K | 320.0K | 203.5K | 167.8K | 77.1K | 100.5K |
| Inventory | 1 | 1 | ||||||||
| Current assets | 60.1M | 95.1M | 77.4M | 111.3M | 146.1M | 133.4M | 11.4M | 12.8M | 9.47M | 39.0M |
| Property, plant and equipment | 578.0K | 898.0K | 1.24M | 1.27M | 382.0K | 624.0K | 877.8K | 1.30M | 2.43M | 3.83M |
| Total assets | 61.9M | 97.2M | 81.6M | 116.2M | 149.5M | 134.7M | 13.1M | 14.2M | 12.3M | 44.0M |
| Accounts payable | 8.09M | 4.82M | 1.97M | 1.96M | 1.44M | 1.37M | 656.3K | 664.8K | 825.2K | 1.13M |
| Current liabilities | 16.4M | 13.4M | 10.4M | 7.81M | 6.56M | 6.12M | 4.78M | 2.92M | 3.95M | 7.80M |
| Long-term debt | 0 | 14.2M | ||||||||
| Total debt | 832.0K | 1.52M | 2.15M | 2.71M | 3.12M | 869.0K | 1.73M | 0 | 1.33M | 2.36M |
| Total liabilities | 16.5M | 14.2M | 11.9M | 9.85M | 9.13M | 6.57M | 5.78M | 4.09M | 5.78M | 24.2M |
| Shareholders' equity | 45.4M | 82.9M | 69.7M | 106.3M | 140.4M | 128.2M | 7.31M | 10.1M | 6.51M | 19.8M |
| Shares outstanding | 68.3M | 66.5M | 44.7M | 44.7M | 42.0M | 36.8M | 8.59M | 3.83M | 733.2K | 30.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -37.9M | -37.7M | -30.9M | -33.8M | -23.0M | -16.3M | -13.3M | -13.2M | -23.3M | -31.0M |
| Capital spending | -44.0K | -80.0K | -582.0K | -1.01M | -205.0K | -211.0K | -67.6K | -5.10K | -101.1K | -823.5K |
| Free cash flow | -38.0M | -37.8M | -31.5M | -34.8M | -23.2M | -16.5M | -13.3M | -13.2M | -23.4M | -31.9M |
| Cash from investing | 1.34M | 13.7M | 36.2M | 38.1M | -131.4M | -211.0K | -67.6K | 22.8K | 24.0M | -24.8M |
| Cash from financing | 2.58M | 53.8M | 0 | 75.0K | 35.5M | 137.3M | 12.1M | 16.4M | -6.38M | 2.30M |
| Dividends paid | -414.0K | -24.0K | -24.2M | -24.2M | -24.2M | -24.2M | -24.2M | |||
| Share buybacks | 75.0K | 35.5M | 24.2M | 12.1M | 32.1M | 25.1M | 24.2M | |||
| Change in cash | -34.0M | 29.8M | 5.31M | 4.40M | -119.0M | 120.8M | -1.26M | 3.23M | -5.69M | -53.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Oct 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 22, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Sep 14, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Aug 26, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 26, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 14, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jul 21, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 16, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 16, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| 8-K · Current report | May 29, 2026 | Material contract | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 25, 2026 | Current report | SEC |
| 8-K · Current report | Feb 24, 2026 | Acquisition or disposal | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Aug 28, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 29, 2025 | Results | SEC |
| 10-Q · Quarterly report | Jul 29, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 17, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 12, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 8, 2025 | Offer document | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 6, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| S-3 · Registration statement | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 11, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jul 1, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 17, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 3, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 8-K · Current report | May 2, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2024 | Offer document | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Sep 26, 2023 | Current report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| 8-K · Current report | Jul 24, 2023 | Current report | SEC |
| 8-K · Current report | Jun 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Meeting outcome | SEC |
| 8-K · Current report | May 4, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 4, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 27, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 8-K · Current report | Mar 2, 2023 | Results | SEC |
| 10-K · Annual report | Mar 2, 2023 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 9, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2023 | Management or board change | SEC |
| SC 13G · Big-stake notice | Jan 26, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 26, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 29, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 3, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 11, 2022 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2022 | Current report | SEC |
| 4 · Change in ownership | Sep 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2022 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2022 | Current report | SEC |
| 8-K · Current report | Sep 6, 2022 | Current report | SEC |
| 8-K · Current report | Aug 4, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 4, 2022 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Jul 12, 2022 | Offer document | SEC |
| SC 13G · Big-stake notice | Jul 8, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2022 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jun 14, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2022 | Meeting outcome | SEC |
| 8-K · Current report | May 5, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 5, 2022 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Apr 26, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 21, 2022 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2022 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 14, 2022 | Other filings | SEC |
| 8-K · Current report | Apr 12, 2022 | Management or board change | SEC |
| 8-K · Current report | Apr 8, 2022 | Current report | SEC |
| S-3 · Registration statement | Apr 5, 2022 | Offer document | SEC |
| 4 · Change in ownership | Mar 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Cardiff Oncology, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 77,795,249
- Fully diluted
- 82,557,154
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 77,795,249 | Nov 3, 2026 |
| Warrants | 4,761,905 | Jul 16, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.31 · expire about Jan 2032 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 77,795,249 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Athena Countouriotis Other companies: BioMarin Pharmaceutical Inc. (Director · Since at least Dec 27, 2023); Passage Bio, Inc. (Chief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics · Since at least Feb 27, 2020); Iovance Biotherapeutics, Inc. (Director · Since at least Jun 10, 2019); Turning Point Therapeutics Inc (President & CEO, Director · Apr 16, 2019 – Aug 17, 2022 · Past); Adverum Biotechnologies Inc (SVP, Chief Medical Officer · Jun 19, 2017 – Feb 15, 2018 · Past); Halozyme Therapeutics, Inc. (SVP and Chief Medical Officer · Jan 5, 2015 – Feb 22, 2017 · Past); Ambit Biosciences Corp (Chief Medical Officer · May 15, 2013 – Nov 10, 2014 · Past) | Director · Sep 14, 2017 – Jun 20, 2019 · Past |
| John Brancaccio Other companies: Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 5, 2026); OKYO Pharma Limited (Director · Since at least May 16, 2022); Accustem Sciences Inc (Board Member · Since at least Dec 1, 2021); Hepion Pharmaceuticals, Inc. (Chairman, Director · Oct 7, 2013 – Feb 19, 2024 · Past); Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jul 4, 2018 · Past); Callisto Pharmaceuticals Inc (Director · Dec 18, 2008 – Jan 17, 2013 · Past) | Director · Jan 23, 2012 – Mar 9, 2022 · Past |
| Gary Jacob Other companies: OKYO Pharma Limited (Chief Development Officer/Director · Since at least May 16, 2022); Virpax Pharmaceuticals, Inc. (Director · Feb 16, 2021 – Jan 1, 2022 · Past); Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Feb 19, 2024 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past) | Director · Jan 23, 2012 – Mar 23, 2021 · Past |
| Matthew L. Posard Other companies: Nautilus Biotechnology, Inc. (Director · Since at least Jun 9, 2021); Halozyme Therapeutics, Inc. (Director · Since at least Mar 27, 2013); Talis Biomedical Corp (Director · Feb 11, 2021 – Jun 9, 2023 · Past); Constellation Alpha Capital Corp (Director · Aug 29, 2019 – Jun 1, 2023 · Past); Illumina, Inc. (Sr VP & General Manager · Feb 2, 2012 – May 30, 2013 · Past) | Chief Commercial Officer · Aug 21, 2015 – Jan 4, 2016 · Past |
| Christopher McGuigan Other companies: Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Dec 3, 2014 · Past); Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jul 24, 2015 · Past); Inhibitex Inc (Director · Sep 19, 2007 – Feb 13, 2012 · Past) | Director · Jan 14, 2013 – Feb 14, 2013 · Past |
| Gabriel Cerrone Other companies: Synergy Pharmaceuticals Inc (Chairman, Director · Aug 3, 2011 – Jul 12, 2013 · Past); Callisto Pharmaceuticals Inc (Director · Jan 26, 2010 – Jan 17, 2013 · Past); Inhibitex Inc (Director · Sep 19, 2007 – Feb 13, 2012 · Past) | Director · Jan 23, 2012 – Feb 14, 2013 · Past |
| Gary W Pace Other companies: Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Mar 6, 2024 · Past); Imunon, Inc. (Director · Mar 15, 2006 – Feb 19, 2010 · Past); ResMed Inc. (Director · Mar 1, 2006 – May 8, 2018 · Past) | Director · Since at least Apr 16, 2020 |
| James Levine Other companies: Kazia Therapeutics Ltd (Chief Financial Officer · Since at least Jun 1, 2026); Cidara Therapeutics Inc (Chief Financial Officer · Dec 3, 2018 – Mar 17, 2021 · Past); Verenium Corp (President & CEO, Director · May 1, 2009 – Oct 31, 2013 · Past) | Chief Financial Officer · Jul 12, 2021 – Mar 11, 2025 · Past |
| Mani Mohindru Other companies: CytomX Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Tvardi Therapeutics, Inc. (CFO & Chief Strategy Officer · Aug 15, 2017 – Dec 2, 2019 · Past); Curis, Inc. (Chief Strategy Officer · Jan 19, 2016 – Feb 14, 2017 · Past) | President & Chief Executive Officer · Since at least Jun 10, 2021 |
| Renee P. Tannenbaum Other companies: ANI Pharmaceuticals, Inc. (Pharm.D., MBA · Since at least Mar 19, 2022); Zogenix Inc (Director · Feb 6, 2015 – Mar 7, 2022 · Past); Sharps Compliance Corp (Director · Feb 29, 2012 – Nov 21, 2013 · Past) | Director · Since at least Jun 10, 2021 |
All 32 people
| Person | Seat |
|---|---|
| Antonius Schuh Other companies: Sorrento Therapeutics, Inc. (Chairman and CEO, Director · Feb 16, 2010 – Feb 16, 2010 · Past); Precipio, Inc. (Director · May 20, 2009 – Feb 18, 2014 · Past) | CEO, Director · Jan 23, 2012 – Jan 4, 2016 · Past |
| Carl B Feldbaum Other companies: Exelixis, Inc. (Director · Feb 8, 2007 – Feb 9, 2023 · Past); Connetics Corp (Director · May 22, 2006 – Dec 29, 2006 · Past) | Director · Dec 31, 2014 – Mar 17, 2015 · Past |
| James O Armitage Other companies: Tesaro Inc (Director · May 9, 2013 – Jan 22, 2019 · Past); Mgi Pharma Inc (Director · Jul 21, 2006 – Jan 28, 2008 · Past) | Director · Since at least Apr 16, 2020 |
| Lale White Other companies: OmniAb, Inc. (Director · Aug 9, 2021 – Aug 9, 2021 · Past); CombiMatrix Corp (Director · Mar 12, 2015 – Nov 14, 2017 · Past) | Director · Since at least Apr 16, 2020 |
| Thomas Phd Adams Other companies: Hepion Pharmaceuticals, Inc. (Director · Sep 20, 2016 – May 18, 2021 · Past); Synergy Pharmaceuticals Inc (Director · Jul 24, 2015 – Jul 3, 2018 · Past) | Executive Chairman, Director · Jan 4, 2016 – Jun 17, 2020 · Past |
| Abba David Poliakoff Other companies: Champions Oncology, Inc. (Director · Mar 31, 2008 – Jan 19, 2021 · Past) | Director · Jan 3, 2008 – Jan 3, 2008 · Past |
| Brigitte Lindsay Other companies: CytomX Therapeutics, Inc. (Chief Accounting Officer, ensuring continuity within the finance function · Jan 27, 2026 – Nov 5, 2026 · Past) | Chief Accounting Officer · Since at least Jan 27, 2026 |
| Fairooz Kabbinavar Other companies: Tocagen Inc (SVP Clinical Development · Apr 15, 2019 – Oct 4, 2019 · Past) | Chief Medical Officer · Jan 30, 2023 – Mar 11, 2025 · Past |
| Kira Sheinerman Other companies: Niki BioSolutions, Inc. (Director · Since at least Jul 20, 2026) | Director · Jun 12, 2008 – Jun 12, 2008 · Past |
| Paul Billings Other companies: MetaStat Inc (Director · May 24, 2017 – Oct 11, 2017 · Past) | Director · Oct 30, 2013 – Jan 23, 2018 · Past |
| Rodney S Markin Other companies: Precipio, Inc. (Director · Mar 1, 2007 – Feb 18, 2014 · Past) | Director · Since at least Feb 19, 2014 |
| Roger Sidhu Other companies: Ernexa Therapeutics Inc. (Chief Medical Officer · Sep 20, 2021 – Sep 20, 2022 · Past) | Chief Medical Officer · Since at least Jun 16, 2025 |
| Stanley Tennant Other companies: Oak Ridge Financial Services, Inc. (Director · Jul 1, 2011 – Dec 31, 2012 · Past) | Director · Jan 23, 2012 – Jun 8, 2018 · Past |
| Steve Zaniboni Other companies: Sorrento Therapeutics, Inc. (Director · Nov 29, 2010 – Nov 29, 2010 · Past) | Former CFO · Jan 23, 2012 – Apr 21, 2016 · Past |
| William J Welch Other companies: Sequenom Inc (President & CEO · Feb 8, 2011 – Jun 10, 2015 · Past) | Chief Executive Officer, Director · Apr 25, 2016 – Jan 30, 2018 · Past |
| Ajay Aggarwal | Chief Operating Officer · Since at least Apr 9, 2026 |
| Joshua Muntner | Chief Financial Officer · Since at least Apr 6, 2026 |
| Katherine L Ruffner | Chief Medical Officer · Jul 6, 2021 – Mar 9, 2022 · Past |
| Leila Alland | Interim Chief Medical Officer · Since at least Oct 27, 2026 |
| Mark Erlander | Chief Executive Officer, Director · Aug 21, 2015 – Mar 11, 2025 · Past |
| Tod Smeal | Chief Scientific Officer · Since at least Jan 10, 2022 |
| Vicki Kelemen | Exec. VP and COO · Jun 18, 2020 – Mar 15, 2023 · Past |
Log in to ask 6ix AI your own questions about Cardiff Oncology, Inc.